drugset
drugset / Trial / NCT06502145

Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome

NCT06502145 ↗

Phase 1 Recruiting 12 enrolled Medical College of Wisconsin
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase I study with a primary objective of determining the recommended phase II dose of iadademstat with azacitidine in adult subjects with myelodysplastic syndrome (MDS).

Timeline

Start
2025-01-10
Primary completion
2026-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Iadademstat Small molecule 75 ug Oral
Subject Iadademstat Small molecule 100 ug Oral
Background Azacitidine Other / unclassified 75 mg/m2 Intravenous

Indications

myelodysplastic syndrome